Liminal BioSciences Inc.
Laval, Qc und Cambridge, England (ots/PRNewswire)
Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”) announced the voting results of its Annual General Meeting (AGM) held virtually on June 5, 2023. A total of 2,235,519 common shares were voted representing 72.02% of the votes of Liminal BioSciences issued and outstanding common shares.
Election of the board members of the company
The six (6) nominees listed in the circular have been elected as directors of the Company, who will serve until the next annual general meeting of shareholders or until their successors are elected or appointed.
|
names of candidates |
For |
Against |
||||
|
Voices |
% |
Voices |
% |
|||
|
Simon Best |
2.021.889 |
98,47 |
31.405 |
1,53 |
||
|
Gary Bridger |
2.028.017 |
98,77 |
25.277 |
1,23 |
||
|
Neil A. Klompas |
2.028.133 |
98,77 |
25.160 |
1,23 |
||
|
Alek Krstajic |
2.027.866 |
98,76 |
25.427 |
1,24 |
||
|
Eugene Siklos |
2.027.982 |
98,77 |
25.311 |
1,23 |
||
|
Timothy Steven Wach |
2.025.888 |
98,67 |
27.406 |
1,33 |
||
Appointment of auditors
PricewaterhouseCoopers LLP have been appointed as the Company’s auditors for a term ending at the next annual general meeting. The board of directors was authorized to determine the remuneration of the auditors.
Detailed voting results for the 2023 AGM are available on SEDAR at www.sedar.com and on the SEC at www.sec.gov.
About BioSciences Inc.
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel and distinctive small molecule therapeutics that modulate the G protein-coupled receptor pathways (GPCRs). The Company is developing proprietary novel small molecule therapeutic candidates with the intention of developing best/leading therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases for which there is significant unmet medical need. It leverages its integrated drug discovery platform, medicinal chemistry expertise and deep understanding of GPCR biology. The Company’s pipeline currently consists of three programs. The candidate selected for clinical development, LMNL6511, a selective antagonist for the GPR84 receptor, is expected to begin a Phase 1 clinical trial in the second half of 2023. The Company is also developing LMNL6326 as an OXER1 receptor antagonist, targeting the treatment of diseases caused by eosinophils, and GPR40 agonists, both of which are in the preclinical stage. In addition to these programs, the Company continues to explore other development opportunities to expand its pipeline.
Liminal BioSciences has active operations in Canada and the United Kingdom.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements are identified through the use of forward-looking terminology. Non-historical statements, including the words “anticipate”, “expect”, “propose”, “plan”, “believe”, “intend”, “estimate”, “target”, “project”, ” should”, “could”, “would”, “may”, “will” and other similar expressions are intended to identify forward-looking statements. These statements include those that relate to Liminal BioSciences’ objectives, strategies and businesses and involve risks and uncertainties. Forward-looking information includes, without limitation, statements regarding the progress of Liminal Biosciences’ product candidates or development programs, including the timing and outcome of potential development of the Company’s R&D programs such as the development of LMNL6511, LMNL6326 and our GPR40 agonist research program; the timing for initiation or nature of pre-clinical studies and clinical studies, including anticipated filing of a clinical study approval or initiation of a Phase 1 clinical study of LMNL6511 in the second half of 2023; The progress of Liminal Biosciences’ product candidates, the outcome of anticipated clinical studies, the analysis of our clinical study data, the potential development of Liminal Biosciences’ R&D programs, the characteristics of our drug candidates, the timing of initiation or the nature of preclinical and clinical studies, and potential therapeutic areas.
These statements are “forward-looking” in that they are based on our current expectations about the markets in which we operate and on various estimates and assumptions. Actual events or results could differ materially from those anticipated in these forward-looking statements if they are known or unknown risks affect our business or if our estimates or assumptions prove incorrect Factors that could cause actual results to differ materially from those described or projected herein include, among others, risks related to: the Company’s ability to develop, manufacture and successfully commercialize product candidates, should that ever occur; the impact of the COVID 19 pandemic and other geopolitical tensions on the Company’s workforce, operations, clinical development, regulatory activities and financial and other business impacts; the availability of funding and resources to pursue R&D projects, clinical development, manufacturing operations or commercial opportunities; the successful and timely initiation or completion of preclinical and clinical studies; the ability to pursue financing or business opportunities in the pharmaceutical industry; uncertainties generally associated with research and development, clinical trials and related regulatory reviews and approvals; our ability to add new development opportunities to our pipeline or enter into strategic partnerships; our ability to continue to comply with Nasdaq Listing Rule 5450(a)(1) to remain listed on the Nasdaq Capital Market; our expected cash flow and our ability to actively seek and complete opportunities to dispose of non-core assets or commercial opportunities related to our assets; and general changes in economic conditions, including the consequences of elevated inflation, bank failures and rising interest rates . For a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to differ materially from our current expectations, please see the Company’s filings and reports with the US Securities and Exchange Commission and the Canadian Securities Administrators, including its annual report on Form 20-F for the year ended December 31, 2022, and other filings and reports that Liminal Biosciences may issue from time to time. Consequently, we cannot guarantee that any particular forward-looking statement will occur. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date of this document. Except as required by applicable securities laws and regulations, we undertake no obligation to update any forward-looking statements contained in this press release, even if new information becomes available, as a result of future events or otherwise.
Corporate Contact, Shrinal Inamdar, Manager, Investor Relations and Communications, [email protected], +1 450.781.0115; Media Contact, Kaitlin Gallagher, [email protected], +1 212.253.8881
View original content:
Original content from: Liminal BioSciences Inc., transmitted by news aktuell